Specific p53 mutations do not impact results of alemtuzumab therapy among patients with chronic lymphocytic leukemia

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F12%3A%230001909" target="_blank" >RIV/65269705:_____/12:#0001909 - isvavai.cz</a>

Alternative codes found

RIV/00216224:14740/12:00062071

Result on the web

<a href="http://dx.doi.org/10.3109/10428194.2012.658794" target="_blank" >http://dx.doi.org/10.3109/10428194.2012.658794</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3109/10428194.2012.658794" target="_blank" >10.3109/10428194.2012.658794</a>

Result language

angličtina

Original language name

Specific p53 mutations do not impact results of alemtuzumab therapy among patients with chronic lymphocytic leukemia

Original language description

A poor prognosis in chronic lymphocytic leukemia (CLL) is associated particularly with the presence of del(17p) affecting tumor suppressor gene TP53. This deletion is in almost all cases of progressive leukemia accompanied by a mutation in the other TP53allele, and in a smaller proportion of patients the TP53 mutation occurs also independently of del(17p). Recently, we demonstrated that patients with CLL harboring a missense mutation located in the p53 DNA-binding motifs (DBMs) (structurally well-defined parts of the DNA-binding domain) manifested a clearly shorter median survival in comparison with those having a missense mutation outside DBMs or a non-missense alteration. However, a limitation of this study resulted from the unpredictable survival impact of diverse therapy given to patients with p53 mutations. Th e therapeutic approach currently taken for patients with CLL with loss and/or mutation of TP53 relies mostly on the use of agents which do not act through DNA damage follow

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2012

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Leukemia & Lymphoma

ISSN

1042-8194

e-ISSN

—

Volume of the periodical

53

Issue of the periodical within the volume

9

Country of publishing house

GB - UNITED KINGDOM

Number of pages

3

Pages from-to

1817-1819

UT code for WoS article

000307301500031

EID of the result in the Scopus database

—